专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5266561A Treatment of type 2 diabetes mellitus 失效
标题翻译：治疗2型糖尿病
公开(公告)号：US5266561A
公开(公告)日：1993-11-30
申请号：US715302
申请日：1991-06-04
申请人： Garth J. S. Cooper , Howard Greene, Jr.
发明人： Garth J. S. Cooper , Howard Greene, Jr.
IPC分类号： A61K38/00 , A61P3/10 , C07K14/575 , C07K16/26 , C61K37/02 , C07K7/06 , C07K7/08 , C07K7/10
CPC分类号： C07K16/26 , C07K14/575 , A61K38/00 , Y10S514/866
摘要： Compounds and methods for blocking the effects of diabetes-associated peptide, or "amylin", a hormone found in the amyloid masses of Type 2 diabetics. This putative hormone has been discovered to function both to inhibit insulin secretion and to inhibit glycogen synthesis. Regulation is accomplished by blocking the binding of amylin or amylin agonists, including calcitonin gene related peptide (CGRP], or biologically active sub-peptides thereof. Inhibitors include substituted peptides or sub-peptides of amylin or CGRP, cross-linked amylin and amylin agonists, synthetic amylin, anti-amylin receptor antibodies and anti-idiotype antibodies, and antibodies directed to amylin and amylin agonist active sites. Other antagonists include organic compounds which can be screened and assayed for anti-amylin effects by disclosed methods.
摘要翻译：用于阻断糖尿病相关肽或“胰岛淀粉样多肽”的作用的化合物和方法，其是在2型糖尿病患者的淀粉样蛋白质中发现的激素。已经发现这种推定的激素既能抑制胰岛素分泌又抑制糖原合成。调节是通过阻断胰岛淀粉样多肽或胰岛淀粉样多肽激动剂（包括降钙素基因相关肽（CGRP）或其生物活性亚肽）的结合来实现的。抑制剂包括取代的肽或胰岛淀粉样多肽或CGRP的亚肽，交联的胰岛淀粉样多肽和胰岛淀粉样多肽激动剂，合成的胰岛淀粉样多肽，抗胰岛淀粉样多肽受体抗体和抗独特型抗体，以及针对胰岛淀粉样多肽和胰岛淀粉样多肽激动剂活性位点的抗体。其它拮抗剂包括通过公开的方法可筛选和测定抗胰淀素作用的有机化合物。

2. 发明授权

US5281581A Treatment of insulin resistance 失效
标题翻译：治疗胰岛素抵抗
公开(公告)号：US5281581A
公开(公告)日：1994-01-25
申请号：US901602
申请日：1992-06-19
申请人： Garth J. S. Cooper , Howard Greene, Jr.
发明人： Garth J. S. Cooper , Howard Greene, Jr.
IPC分类号： A61K38/00 , A61P3/10 , C07K14/575 , C07K16/26 , A61K37/02 , C07K7/08 , C07K7/10
CPC分类号： C07K16/26 , C07K14/575 , A61K38/00 , Y10S514/866
摘要： Compounds and methods for blocking the effects of diabetes-associated peptide, or "amylin", a hormone found in the amyloid masses of Type 2 diabetics. This putative hormone has been discovered to function both to inhibit insulin secretion and to inhibit glycogen synthesis. Regulation is accomplished by blocking the binding of amylin or amylin agonists, including calcitonin gene related peptide (CGRP], or biologically active sub-peptides thereof. Inhibitors include substituted peptides or sub-peptides of amylin or CGRP, cross-linked amylin and amylin agonists, synthetic amylin, anti-amylin receptor antibodies and anti-idiotype antibodies, and antibodies directed to amylin and amylin agonist active sites. Other antagonists include organic compounds which can be screened and assayed for anti-amylin effects by disclosed methods.
摘要翻译：用于阻断糖尿病相关肽或“胰岛淀粉样多肽”的作用的化合物和方法，其是在2型糖尿病患者的淀粉样蛋白质中发现的激素。已经发现这种推定的激素既能抑制胰岛素分泌又抑制糖原合成。通过阻断胰岛淀粉样多肽或胰岛淀粉样多肽激动剂（包括降钙素基因相关肽（CGRP））或其生物活性亚肽的结合来完成调节。抑制剂包括取代的肽或胰岛淀粉样多肽或CGRP的亚肽，交联的胰岛淀粉样多肽和胰岛淀粉样多肽激动剂，合成的胰岛淀粉样多肽，抗胰岛淀粉样多肽受体抗体和抗独特型抗体，以及针对胰岛淀粉样多肽和胰岛淀粉样多肽激动剂活性位点的抗体。其他拮抗剂包括可以通过公开的方法筛选和测定抗胰淀素效应的有机化合物。

3. 发明授权

US5280014A Treatment of obesity and essential hypertension and related disorders 失效
公开(公告)号：US5280014A
公开(公告)日：1994-01-18
申请号：US737794
申请日：1991-07-18
申请人： Garth J. S. Cooper , Brendan Leighton
发明人： Garth J. S. Cooper , Brendan Leighton
IPC分类号： A61K38/00 , A61K38/22 , C07K14/575 , C07K16/26 , A61K37/02 , C07K7/10
CPC分类号： C07K14/575 , A61K38/225 , C07K16/26 , A61K38/00
摘要： The administration of antagonists and blockers of amylin or CGRP or both for the treatment of obesity and essential hypertension and associated lipid disorders and atherosclerosis.

4. 发明授权

US06884575B2 Phosphoprotein target for insulin and its antagonists 失效
标题翻译：胰岛素及其拮抗剂的磷蛋白靶标
公开(公告)号：US06884575B2
公开(公告)日：2005-04-26
申请号：US10114540
申请日：2002-04-01
申请人： Garth J. S. Cooper , Aimin Xu , Yu Wang
发明人： Garth J. S. Cooper , Aimin Xu , Yu Wang
IPC分类号： G01N33/50 , A61K45/00 , A61P3/00 , A61P3/10 , C12N15/09 , C12Q1/02 , G01N33/15 , G01N33/68 , G01N33/74 , C12Q1/00
CPC分类号： G01N33/6893 , G01N33/74 , G01N2500/02 , G01N2500/10 , G01N2800/042
摘要： The invention provides methods for diagnosing and treating individuals with insulin resistance.
摘要翻译：本发明提供了用于诊断和治疗具有胰岛素抵抗的个体的方法。

5. 发明授权

US5641744A Treatment of diabetes mellitus 失效
标题翻译：治疗糖尿病
公开(公告)号：US5641744A
公开(公告)日：1997-06-24
申请号：US341342
申请日：1994-11-17
申请人： Garth J. S. Cooper
发明人： Garth J. S. Cooper
IPC分类号： A61K38/23 , A61K38/00 , A61K38/22 , A61K38/27 , A61K38/28 , A61K45/00 , A61P3/08 , A61P3/10 , C07K14/575 , A61K38/16
CPC分类号： A61K38/225 , A61K33/30 , A61K38/28 , C07K14/575 , A61K38/00
摘要： The present invention relates to methods of preparing a product or a composition containing amylin or amylin with insulin for treating diabetes mellitus.
摘要翻译：本发明涉及制备含有胰岛淀粉样多肽或胰岛淀粉样多肽的产品或组合物与用于治疗糖尿病的胰岛素的方法。

6. 发明授权

US5124314A Pharmaceutical compositions containing amylin 失效
标题翻译：含有胰岛淀粉样多肽的药物组合物
公开(公告)号：US5124314A
公开(公告)日：1992-06-23
申请号：US715031
申请日：1991-06-10
申请人： Garth J. S. Cooper
发明人： Garth J. S. Cooper
IPC分类号： A61K38/23 , A61K38/00 , A61K38/22 , A61K38/27 , A61K38/28 , A61K45/00 , A61P3/08 , A61P3/10 , C07K14/575
CPC分类号： A61K38/225 , A61K33/30 , A61K38/28 , C07K14/575 , A61K38/00
摘要： The present invention relates to pharmaceutical compositions for use in treating diabetes Mellitus or hypoglycemia containing Amylin as the effective additive.
摘要翻译：本发明涉及用于治疗含有胰岛淀粉样多肽的糖尿病或低血糖作为有效添加剂的药物组合物。

7. 发明授权

US08034799B2 Preventing and/or treating cardiovascular disease and/or associated heart failure 有权
标题翻译：预防和/或治疗心血管疾病和/或相关的心力衰竭
公开(公告)号：US08034799B2
公开(公告)日：2011-10-11
申请号：US11221298
申请日：2005-09-07
申请人： Garth J. S. Cooper , John R. Baker
发明人： Garth J. S. Cooper , John R. Baker
IPC分类号： A61K31/33 , A61K31/315 , A61K31/195 , A61K31/185 , A61K31/07 , A61K33/32
CPC分类号： A61K31/197 , A61K31/13 , A61K31/198 , A61K31/30 , A61K31/38 , A61K31/45 , A61K33/30 , A61K33/34 , A61K45/06
摘要： Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems, (iv) plaque rupture of atheromatous lesions of major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral arteries and the popliteal arteries, (v) diabetes or the complications of diabetes.
摘要翻译：提供了用于减少铜值的方法，例如，治疗，预防或改善组织损伤，例如可能由（i）心脏病（例如心肌病或心肌炎）引起的组织损伤，例如特发性心肌病，包括糖尿病性心肌病，酒精性心肌病，药物性心肌病，缺血性心肌病，高血压性心肌病等的代谢性心肌病，（ii）主要血管（大血管病）如动脉粥样硬化性疾病如冠状动脉，颈动脉，脑血管动脉，肾动脉，髂动脉，股动脉和al动脉，（iii）毒性，药物诱导和代谢（包括小血管的高血压和/或糖尿病性疾病（微血管疾病），例如视网膜小动脉，肾小球小动脉，神经紧张，心脏小动脉和相关毛细血管床眼睛，肾脏，心脏和中枢和周围神经系统的斑块破裂，（iv）主要血管的动脉粥样硬化病变的斑块破裂，例如主动脉，冠状动脉，颈动脉，脑血管动脉，肾脏动脉，髂动脉，股动脉和al动脉，（v）糖尿病或糖尿病并发症。

8. 发明授权

US6048514A Amylin activity assays 失效
标题翻译：胰岛淀粉样多肽活性测定
公开(公告)号：US6048514A
公开(公告)日：2000-04-11
申请号：US422747
申请日：1995-04-14
申请人： Andrew A. Young , Garth J. S. Cooper , Timothy J. Rink
发明人： Andrew A. Young , Garth J. S. Cooper , Timothy J. Rink
IPC分类号： A61K49/00 , G01N33/66 , G01N33/74 , A61K38/22 , G01N33/15
CPC分类号： A61K49/0008 , A61K49/0004 , G01N33/74 , G01N33/66 , Y10S514/866 , Y10S514/884
摘要： Novel methods for use in identifying or assaying compounds which can simulate the ability of amylin to cause hyperlactemia and hyperglycemia in in vivo biological models, or for use in evaluating the potency of compounds known or suspected to simulate these actions of amylin, which involve introducing test samples into in vivo test systems and determining the presence or amount of a rise in lactate, or determining the presence or amount of a rise in lactate and a rise in glucose, following test sample administration.
摘要翻译：用于鉴定或测定化合物的新方法，其可以模拟胰岛淀粉样多肽在体内生物模型中引起高血糖和高血糖的能力，或用于评估已知或怀疑模拟胰岛淀粉样多肽的这些作用的化合物的效力，其涉及引入测试样品进入体内测试系统并确定乳酸盐升高的存在或数量，或测定样品给药后确定乳酸盐升高的存在或量以及葡萄糖的升高。

9. 发明授权

US5364841A Treatment of obesity and essential hypertension and related disorders 失效
标题翻译：治疗肥胖和原发性高血压及相关疾病
公开(公告)号：US5364841A
公开(公告)日：1994-11-15
申请号：US81033
申请日：1993-06-21
申请人： Garth J. S. Cooper , Brendan Leighton
发明人： Garth J. S. Cooper , Brendan Leighton
IPC分类号： A61K38/00 , A61K38/22 , C07K14/575 , C07K16/26 , C07K7/06 , A61K37/02 , C07K7/08 , C07K7/10
CPC分类号： C07K14/575 , A61K38/225 , C07K16/26 , A61K38/00
摘要： The administration of antagonists and blockers of amylin or CGRP or both for the treatment of obesity and essential hypertension and associated lipid disorders and atherosclerosis.
摘要翻译：施用胰岛淀粉样多肽或CGRP或两者的拮抗剂和阻断剂用于治疗肥胖症和原发性高血压以及相关的脂质障碍和动脉粥样硬化。

10. 发明授权

US5234906A Hyperglycemic compositions 失效
标题翻译：高性能组合物
公开(公告)号：US5234906A
公开(公告)日：1993-08-10
申请号：US640478
申请日：1991-01-10
申请人： Andrew Young , Garth J. S. Cooper
发明人： Andrew Young , Garth J. S. Cooper
IPC分类号： A61K31/56 , A61K38/22 , A61K38/23 , A61K38/26 , A61K49/00 , A61P3/08
CPC分类号： A61K49/0008 , A61K38/22 , A61K38/225 , A61K38/26
摘要： Compositions having amylin or an amylin agonist and a glucagon compound, particularly peptide compounds, for the control of glucose production in mammals are provided. The compositions are useful in the treatment of hypoglycemia, including acute hypoglycemic conditions such as those brought on by insulin overdose and the overuse of oral hypoglycemic agents.
摘要翻译：提供了具有胰岛淀粉样多肽或胰岛淀粉样多肽激动剂和用于控制哺乳动物葡萄糖产生的胰高血糖素化合物，特别是肽化合物的组合物。该组合物可用于治疗低血糖症，包括急性低血糖病症，例如胰岛素过量引起的疾病和过量使用口服降糖药。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式